2019
Nerve Growth Factor Improves the Outcome of Type 2 Diabetes—Induced Hypotestosteronemia and Erectile Dysfunction
Wu Y, Yang C, Meng F, Que F, Xiao W, Rao H, Wan Y, Taylor HS, Lu L. Nerve Growth Factor Improves the Outcome of Type 2 Diabetes—Induced Hypotestosteronemia and Erectile Dysfunction. Reproductive Sciences 2019, 26: 386-393. PMID: 29724155, DOI: 10.1177/1933719118773421.Peer-Reviewed Original ResearchConceptsNerve growth factorErectile dysfunctionTotal testosteroneFree testosteroneDiabetes-induced erectile dysfunctionNGF treatmentGrowth factorHyperglycemia-induced downregulationErectile Function scoreIIEF-5 scoreSerum total testosteroneType 2 diabetesMouse Leydig cellsSteroidogenic acute regulatory proteinDiabetic malesSensorimotor polyneuropathySerum testosteroneFunction scoresAcute regulatory proteinInternational IndexClinical studiesED outcomesCytochrome P450 11A1Testosterone biosynthesisLeydig cells
2017
Artificial human antigen‐presenting cells are superior to dendritic cells at inducing cytotoxic T‐cell responses
Li H, Shao S, Cai J, Burner D, Lu L, Chen Q, Minev B, Ma W. Artificial human antigen‐presenting cells are superior to dendritic cells at inducing cytotoxic T‐cell responses. Immunology 2017, 152: 462-471. PMID: 28664991, PMCID: PMC5629434, DOI: 10.1111/imm.12783.Peer-Reviewed Original ResearchMeSH KeywordsAntigen PresentationCancer VaccinesCell SurvivalCytotoxicity, ImmunologicDelayed-Action PreparationsDendritic CellsDrug CompoundingDrug LiberationHumansInhibitor of Apoptosis ProteinsKineticsLactic AcidLipopolysaccharidesMART-1 AntigenMCF-7 CellsNanoparticlesNeoplasmsPeptide FragmentsPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerSolubilitySurvivinT-Lymphocytes, CytotoxicConceptsArtificial antigen-presenting cellsCytotoxic T lymphocytesT cell responsesDendritic cellsAntigen-presenting cellsTumor antigenic peptidesCTL responsesMature DCsT cellsAntigen-specific cytotoxic T lymphocytesAntigen-specific CTL responsesHuman antigen-presenting cellsCytotoxic T cell responsesHuman immature dendritic cellsEffective T cell responsesAntigenic peptidesEffective CTL responsesTumor antigen presentationCancer cellsImmature dendritic cellsMature dendritic cellsT-cell immunotherapyMHC class IMHC class I-peptide complexesWarrants further assessment
2014
Effect on metabolic enzymes and thyroid receptors induced by BDE-47 by activation the pregnane X receptor in HepG2, a human hepatoma cell line
Hu X, Zhang J, Jiang Y, Lei Y, Lu L, Zhou J, Huang H, Fang D, Tao G. Effect on metabolic enzymes and thyroid receptors induced by BDE-47 by activation the pregnane X receptor in HepG2, a human hepatoma cell line. Toxicology In Vitro 2014, 28: 1377-1385. PMID: 25063376, DOI: 10.1016/j.tiv.2014.07.004.Peer-Reviewed Original ResearchConceptsPregnane X receptorThyroid receptorX receptorRegulation of CYP3A4Microsomal phase ITetra-bromodiphenyl etherHuman pregnane X receptorDual-luciferase reporterHepG2 cell modelBDE-47Human hepatoma cell lineDetailed underlying mechanismsMetabolic enzymesHepatoma cell lineThyroid hormonesBDE-47 treatmentToxicological evidencePhase IHealth effectsThyroid disruptionReceptorsExpression levelsHPXRUnderlying mechanismUGT1A3
2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer
Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 2011, 31: 4559-4566. PMID: 22139083, PMCID: PMC3342446, DOI: 10.1038/onc.2011.539.Peer-Reviewed Original ResearchMeSH Keywords3' Untranslated RegionsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBRCA1 ProteinBRCA2 ProteinCarboplatinCell Line, TumorCell SurvivalDrug Resistance, NeoplasmFemaleGenotypeHumansKaplan-Meier EstimateMiddle AgedMultivariate AnalysisMutationNeoplasms, Glandular and EpithelialOvarian NeoplasmsPaclitaxelPolymorphism, Single NucleotidePrognosisProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsRNA InterferenceTreatment OutcomeConceptsEpithelial ovarian cancerEOC patientsKRAS-variantOvarian cancerPoor outcomeCancer riskTumor biologyPlatinum resistanceComplete clinical dataBiomarkers of outcomeDirect targetingEOC cell growthKnown BRCA mutationsFuture treatment approachesSubset of tumorsPlatinum chemotherapy resistanceCell linesNeoadjuvant chemotherapyBRCA mutationsClinical dataTreatment approachesChemotherapy resistanceKRAS oncogeneMultivariate analysisPatients